Eligibility criteria
Condition
Overactive Bladder (OAB)
Sex
Females and Males
Age
20 + years
Inclusion criteria
Show details
- Patients prescribed fesoterodine (Toviaz).
Exclusion criteria
Show details
- There are no exclustion criteria
You are here
Drug Use Investigation for Toviaz
NCT01936870
Last updated on November 13, 2019
About this Study
The purpose of this study is to collect effectiveness and safety information of fesoterodine related to their appropriate use in daily practice.
NCT01936870
Pfizer
Completed
Drug Use Investigation for Toviaz
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title | Drug Use Investigation for Toviaz | |||
| Official Title | Drug Use Investigation For Toviaz | |||
| Brief Summary | The purpose of this study is to collect effectiveness and safety information of fesoterodine related to their appropriate use in daily practice. | |||
| Detailed Description | Not Provided | |||
| Study Type | Observational | |||
| Study Design | Observational Model: Case-Only Time Perspective: Prospective | |||
| Target Follow-Up Duration | Not Provided | |||
| Biospecimen | Not Provided | |||
| Sampling Method | Probability Sample | |||
| Study Population | Patients prescribed fesoterodine (Toviaz) by investigators involved in protocol A0221096. | |||
| Condition | Overactive Bladder (OAB) | |||
| Intervention | Drug: Fesoterodine (Toviaz) Fesoterodine 4 mg or 8 mg orally. Toviaz will be dosed according to labeling. The administration and duration of therapy will be determined by the treating physician to meet the patient's needs for treatment. | |||
| Study Groups/Cohorts | Fesoterodine (Toviaz) Intervention: Drug: Fesoterodine (Toviaz) | |||
| Publications * | Not Provided | |||
| * Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status | Completed | |||
| Actual Enrollment | 2521 | |||
| Original Estimated Enrollment | 2000 | |||
| Actual Study Completion Date | May 2016 | |||
| Actual Primary Completion Date | May 2016 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender |
| |||
| Ages | 20 Years and older (Adult, Older Adult) | |||
| Accepts Healthy Volunteers | No | |||
| Contacts | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries | Not Provided | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number | NCT01936870 | |||
| Other Study ID Numbers | A0221096 | |||
| Has Data Monitoring Committee | No | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement | Not Provided | |||
| Responsible Party | Pfizer | |||
| Study Sponsor | Pfizer | |||
| Collaborators | Not Provided | |||
| Investigators |
| |||
| PRS Account | Pfizer | |||
| Verification Date | February 2017 | |||
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
BY PHONE
Pfizer Clinical Trials Contact Center
1-800-718-1021